Shopping Cart
- Remove All
Your shopping cart is currently empty
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It indirectly decreases osteoclast differentiation by reducing the RANKL/OPG ratio and directly increases osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways, thereby inducing bone formation via Runx2.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $149 | In Stock |
| Description | Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It indirectly decreases osteoclast differentiation by reducing the RANKL/OPG ratio and directly increases osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways, thereby inducing bone formation via Runx2. |
| In vitro | Muramyl dipeptide increases the protein expression of Runx2 in a dose-dependent manner (0.1-10 μg/mL; 24 hours)[1]. It also enhances the mRNA levels of Runx2 in a dose-dependent manner (0.1-10 μg/mL; 6 hours)[2]. Muramyl dipeptide indirectly attenuates osteoclast differentiation by reducing the RANKL/OPG ratio[2]. |
| In vivo | Muramyl dipeptide can be used for animal modeling to establish sepsis models. Muramyl dipeptide (1.25 mg/kg; intraperitoneal injection; twice) alleviates osteoporosis-induced bone loss[2]. |
| Synonyms | MDP |
| Molecular Weight | 492.48 |
| Formula | C19H32N4O11 |
| Cas No. | 53678-77-6 |
| Smiles | C[C@H](NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(=O)N[C@H](CCC(O)=O)C(N)=O |
| Relative Density. | 1.390 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature,keep away from moisture | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (101.53 mM), Sonication is recommended. H2O: 20 mg/mL (40.61 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.15 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.